Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Monumental Year Ahead For Korean Pharmas As New US Approvals Eyed

Executive Summary

2019 could be a monumental year for the South Korean pharma industry, as several new drug assets await the green light from the US FDA.
Advertisement

Related Content

AbbVie Defends Humira With Aggressive Discount In First EU Tender
Spectrum To Test Poziotinib's Potential As First Line Treatment Of Exon 20 Mutant NSCLC
ViroMed's Plasmid DNA Facility Buy Addresses Key Potential US Regulatory Hurdle
Spectrum Gears Up To File Rolontis, Stresses Patient Access
Committing To Drug Development In World's Biggest Market: SK's Story
BIO Korea 2016: SillaJen On Maximizing Value Of Pexa-Vec

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124419

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel